[1] National Health Commission Disease Control and Prevention Bureau. Report on the Nutrition and Chronic Disease Status of Chinese Residents (2020)(中国居民营养与慢性病状况报告(2020)[M] 2020)(中国居民营养与慢性病状况报告(2020)[M].Beijing: People's Medical Publishing House, 2021. [2] Chinese Diabetes Society, National Office for Primary Diabetes Care. National Handbook for the Prevention and Control of Diabetes in Primary Care(2022)[J].Chinese Journal of Internal Medicine(中华内科杂志),2022, 61(3): 249-262. [3] NAKHLA M, NAIR A, BALANI P, et al.Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: a Real-World Pharmacovigilance Study[J].Cardiovascular Drugs and Therapy, 2024, 9: 1-11. [4] HE L, LI Q, YANG Y, et al.Pharmacovigilance Study of GLP-1 Receptor Agonists for Metabolic and Nutritional Adverse Events[J].Frontiers in Pharmacology, 2024, 15: 1416985-1416998. [5] SI HJ, ZHAO LM, CAI S, et al.Medication Guidelines for Glucagon-Like Peptide-l Receptor Agonist(2023 Edition)[J].China Pharmacy(中国药房),2023, 34(11): 1281-1292. [6] HANSSEN R, RIGOUX L, KUZMANOVIC B, et al.Liraglutide Restores Impaired Associative Learning in Individuals with Obesity[J].Nature Metabolism, 2023, 5(8): 1352-1363. [7] XIE ZY, HUANG SY, HU X, et al. Clinical Comprehensive Evaluation of 6 GLP-1RAs for the Treatment of Type 2 Diabetes Mellitus[J/OL].Chin J Hosp Pharm(中国医院药学杂志),(2024-09-29)[2024-10-11].https://link.cnki.net/urlid/42.1204.R.20240929.1245.002. [8] YANG Q, WANG J, WANG M, et al.Stratified Analysis of the Association between Anti-Obesity Medications and Digestive Adverse Events: a Real-World Study Based on the FDA Adverse Event Reporting System Database[J].BMC Pharmacology and Toxicology, 2024, 25(1): 64-76. [9] ALENZI K A, ALSUHAIBANI D, BATARFI B, et al.Pancreatitis with Use of New Diabetic Medications: a Real-World Data Study Using The Post-Marketing FDA Adverse Event Reporting System(FAERS) Database[J].Frontiers in Pharmacology, 2024, 15: 1364110-1364120. [10] BHATTACHARYYA M, MILLER LE, MILLER AL, et al.Mortality and Serious Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists: a Pharmacovigilance Study Using the FDA Adverse Event Reporting System[J].Cureus, 2024, 16(8): e65989-e65998. [11] ZHOU RS, LU PW, CHEN JH, et al.Application of Adverse Drug Reaction of Data Mining in Pharmacovigilance[J].Chin J Mod Appl Pharm(中国现代应用药学) , 2024, 41(6): 864-870. [12] DONG S, SUN C.Can Glucagon-Like Peptide-1 Receptor Agonists Cause Acute Kidney Injury? An Analytical Study Based on Post-Marketing Approval Pharmacovigilance Data[J].Front Endocrinol(Lausanne),2022, 13: 1032199-1032209. [13] JIANG Y, ZHOU L, SHEN Y, et al.Safety Assessment of Brexpiprazole: Real-World Adverse Event Analysis from the FAERS Database[J].Journal of Affective Disorders, 2024, 346: 223-229. [14] VAN PUIJENBROEK EP, DIEMONT WL, VAN GROOTHEEST K.Application of Quantitative Signal Detection in the Dutch Spontaneous Reporting System for Adverse Drug Reactions[J].Drug Safety, 2003, 26(5): 293-301. [15] BELLIDO D, ABELLAN P, PALOMAR JMR, et al.Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: the BASAL-LIXI Study[J].Current Therapeutic Research, 2018, 89: 37-42. [16] GORGOJO-MARTINEZ JJ, MEZQUITA-RAYA P, CARRETERO-GOMEZ J, et al.Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: a Multidisciplinary Expert Consensus[J].Journal of Clinical Medicine, 2022, 12(1): 145-162. [17] REHFELD JF, KNOP FK, ASMAR M.Gastrin Secretion in Normal Subjects and Diabetes Patients is Inhibited by Glucagon-Like Peptide 1: a Role in the Gastric Side Effects of GLP-1-Derived Drugs?[J].Scandinavian Journal of Gastroenterology, 2019, 54(12): 1448-1451. [18] LIU L, CHEN J, WANG L, et al.Association between Different GLP-1 Receptor Agonists and Gastrointestinal Adverse Reactions: a Real-World Disproportionality Study Based on FDA Adverse Event Reporting System Database[J].Frontiers in Endocrinology, 2022, 13: 1043789-1043799. [19] Pharmaceuticals and Medical Devices Agency. Summary of Investigation Results Preparations Containing GLP-1 Receptor Agonists and Tirzepatide[EB/OL].(2023-02-14)[2024-04-14].https://www.pmda.go.jp/files/000250523. [20] HE L, WAND J, PING F, et al.Association of Glucagon-Like Peptide-1 Receptor Agonist Use with Risk of Gallbladder and Biliary Diseases: a Systematic Review and Meta-Analysis of Randomized Clinical Trials[J].JAMA Internal Medicine, 2022, 182(5): 513-519. [21] AYOUB WA, KUMAR AA, NAGUIB HS, et al.Exenatide-Induced Acute Pancreatitis[J].Endocrine Practice, 2010, 16(1): 80-83. [22] BUTLER ADE, CAMPBELL-THOMPSON M, GURLO T, et al.Marked Expansion of Exocrine and Endocrine Pancreas with Incretin Therapy in Humans with Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors[J].Diabetes, 2013, 62(7): 2595-2604. [23] BUTLER PC, ELASHOFF M, ELASHOFF R, et al.A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 Therapies Safe?[J].Diabetes Care, 2013, 36(7): 2118-2125. [24] NAUCK MA.A Critical Analysis of the Clinical Use of Incretin Based Therapies: the Benefits by Far Outweigh the Potential Risks[J].Diabetes Care, 2013, 36(7): 2126-2132. [25] DENG H, YANG F, MA X, et al.Long-Term Liraglutide Administration Induces Pancreas Neogenesis in Adult T2DM Mice[J].Cell Transplantation,2020, 29: 0963689720927392-0963689720927407. [26] BEZIN J, GOUVERNEUR A, PENICHON M, et al.GLP-1 Receptor Agonists and the Risk of Thyroid Cancer[J].Diabetes Care, 2023, 46(2): 384-390. [27] YANG Z, LV Y, YU M, et al.GLP-1 Receptor Agonist-Associated Tumor Adverse Events: a Real-World Study from 2004 to 2021 Based on FAERS[J].Frontiers in Pharmacology, 2022, 13: 925377-925387. [28] JENSTERLE M, RIZZO M, HALUZIK M, et al.Efficacy of GLP-1 RA Approved for Weight Management in Patients with or without Diabetes: a Narrative Review[J].Advances in Therapy, 2022, 39(6): 2452-2467. [29] WILDING JPH.Medication Use for the Treatment of Diabetes in Obese Individuals[J].Diabetologia, 2018, 61(2): 265-272. [30] CDR, NMPA. Pharmacovigilance flash: UK Warns That Risk of Diabetes Ketoacidosis Caused by Combination of GLP-1 RA and Insulin[EB/OL].(2019-07-29)[2024-04-14].https://cdr.adr.org.cn/drug_1/aqjs_1/drug_aqjs_jjkx/201907/t20190729_46676.html. [31] ABCOUWER SF, GARDNER TW.Diabetic Retinopathy: Loss of Neuroretinal Adaptation to the Diabetic Metabolic Environment[J].Annals of the New York Academy of Sciences, 2014, 1311(1): 174-190. [32] HOLSCHER C.Potential Role of Glucagon-Like Peptide-1(GLP-1) in Neuroprotection[J].CNS Drugs, 2012, 26(10): 871-882. [33] ZHENG D, LI N, HOU R, et al.Glucagon-Like Peptide-1 Receptor Agonists and Diabetic Retinopathy: Nationwide Cohort and Mendelian Randomization Studies[J].BMC Medicine, 2023, 21(1): 40-50. [34] VARADHAN L, HUMPHREYS T, WALKER AB, et al.The Impact of Improved Glycaemic Control with GLP-1 Receptor Agonist Therapy on Diabetic Retinopathy[J].Diabetes Research and Clinical Practice, 2014, 103(3): 37-39. [35] SUN YX, LIU XH, YANG M, et al.Data Mining for Adverse Reaction Signals of Fluoroquinolones in Children Based on the FAERS Database[J].Chin J Hosp Pharm(中国医院药学杂志),2023, 43(17): 1943-1948. |